➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Express Scripts
McKinsey
McKesson
Baxter

Last Updated: November 30, 2020

DrugPatentWatch Database Preview

Claims for Patent: 4,474,752

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 4,474,752
Title: Drug delivery system utilizing thermosetting gels
Abstract:Present invention provides a unique drug delivery device for delivering drug by injection into a body. The drug delivery system comprises the drug and polymer which is a liquid at room temperature and a semi-solid or gel at the body temperature.
Inventor(s): Haslam; John L. (Lawrence, KS), Higuchi; Takeru (Lawrence, KS), Mlodozeniec; Arthur R. (Lawrence, KS)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:06/495,240
Patent Claims:1. An aqueous pharmaceutical composition for injection into a body to treat a condition requiring pharmacological treatment comprising

a. 10% to 50% by weight of a polymer of the formula ##STR2## wherein w is an integer of from 2 to 6 containing approximately 40% to 80% poly(oxyethylene) and approximately 20 to 60% poly(oxypropylene) and having a molecular weight of 7,000 to 50,000; and x and y are any integer within the above constraints; and

b. a pharmacologically effective amount of drug selected from the group consisting of antibacterial substances, antihistamines and decongestants, anti-inflammatories, antiparasitics, antiviral, local anesthetics, antifungal, amebecidal, or trichomonocidal agents, analgesics, antiarthritics, antiasthmatics, anticoagulants, anticonvulsants, antidepressants, antidiabetics, antineoplastics, antipsychotics, antihypertensives and muscle relaxants; and

c. a pharmaceutically acceptable acid or base being in sufficient quantity to adjust the pH of the composition to range from 2 to 9 and wherein the composition is liquid at about room temperature or below.

2. The composition of claim 1 wherein the polymer is one where w=2.

3. The composition of claim 1 wherein the polymer is Tetronic.RTM. 1307.

4. The composition of claim 1 wherein the gel-sol transition temperature of the composition is room temperature or below and said composition is liquid at this temperature.

5. The composition of claim 1 wherein said pharmaceutical composition is injected subcutaneously or intramuscularly.

6. The composition of claim 5 wherein said pharmaceutical composition once injected may serve as a prolonged release site or depot.

7. The composition of claim 1 wherein the antibacterial substances are selected from the group consisting of beta-lactam antibiotics, tetracyclines, chloramphenicol, neomycin, gramicidin, bacitracin, sulfonamides, aminoglycoside antibiotics, tobramycin, nitrofurazone, nalidixic acid and analogs and the antimicrobial combination of fludalanine/pentizidone.

8. The composition of claim 1 wherein the antihistaminics and decongestants are selected from the group consisting of perilamine, chlorpheniramine, tetrahydrozoline and antazoline.

9. The composition of claim 1 wherein the anti-inflammatory drugs are selected from the group consisting of cortisone, hydrocortisone, betamethasone, dexamethasone, fluocortolone, prednisolone, triamcinolone, indomethacin, sulindac and its salts and corresponding sulfide.

10. A composition of claim 1 wherein the antiparasitic compound is ivermectin.

11. The composition of claim 1 wherein the antiviral effective compounds are selected from the group consisting of acyclovir and interferon.

12. The composition of claim 1 wherein the analgesic drug is selected from the group consisting of diflunisal, aspirin or acetaminophen.

13. The composition of claim 1 wherein the antiarthritics are selected from the group consisting of phenylbutazone, indomethacin, sulindac, its salts and corresponding sulfide, dexamethasone, ibuprofen, allopurinol, oxyphenbutazone or probenecid.

14. The composition of claim 1 wherein the antiasthma drugs are selected from the group consisting of theophylline, ephedrine, beclomethasone dipropionate and epinephrine.

15. The composition of claim 1 wherein the anticoagulants are selected from the group consisting of heparin, bishydroxycoumarin, and warfarin.

16. The composition of claim 1 wherein the anticonvulsants are selected from the group consisting of diphenylhydantoin and diazepam.

17. The composition of claim 1 wherein the antidepressants are selected from the group consisting of amitriptyline, chlordiazepoxide perphenazine, protriptyline, imipramine and doxepin.

18. The composition of claim 1 wherein the antidiabetics are selected from the group consisting of insulin, somatostatin and its analogs, tolbutamide, tolazamide, acetohexamide and chlorpropamide.

19. The composition of claim 1 wherein the antineoplastics are selected from the group consisting of adriamycin, flurouracil, methotrexate and asparaginase.

20. The composition of claim 1 wherein the antipsychotics are selected from the group consisting of prochlorperazine, lithium carbonate, lithium citrate, thioridazine, molindone, fluphenazine, trifluoperazine, perphenazine, amitriptyline and triflupromazine.

21. The composition of claim 1 wherein the antihypertensives are selected from the group consisting of spironolactone, methyldopa, hydralazine, clonidine, chlorothiazide, deserpidine, timolol, propranolol, metoprolol, prazosin hydrochloride and reserpine.

22. The composition of claim 1 wherein the muscle relaxants are selected from the group consisting of succinylcholine chloride, danbrolene, cyclobenzaprine, methocarbamol and diazepam.

23. The composition of claim 1 which includes a buffering agent or salt of from 0 to 5% by weight of the composition.

24. The composition of claim 23 wherein the buffering agent or salt is selected from the group consisting of alkali or alkali earth carbonates, chlorides, sulfates, phosphates, bicarbonates, citrates, borates, acetates and succinates.

25. The composition of claim 1 which includes from 0.001% to 5% by weight of the composition of a preservative.

26. The composition of claim 25 wherein the preservatives are selected from the group consisting of sodium bisulfite, sodium thiosulfate, ascorbate, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric borate, parabens, benzylalcohol and phenylethanol.

27. The composition of claim 1 wherein the acid or base is selected from the group consisting of hydrochloric acid or sodium hydroxide.

28. A method of treating a condition requiring pharmacological treatment which comprises injecting into a body cavity a liquid drug delivery vehicle comprising:

a. 10% to 50% by weight of a polymer of the formula ##STR3## wherein w is an integer of from 2 to 6 containing approximately 40% to 80% poly(oxyethylene) and approximately 20-60% poly(oxypropylene) and having a molecular weight of 7,000 to 50,000; and x and y are any integers within the above constraints; and

b. a pharmacologically effective amount of drug selected from the group consisting of antibacterial substances, antihistamines and decongestants, anti-inflammatories, antiparasitics, antiviral, local anesthetics, antifungal, amebecidal, or trichomonocidal agents, analgesics, antiarthritics, antiasthmatics, anticoagulants, anticonvulsants, antidepressants, antidiabetics, antineoplastics, antipsychotics, antihypertensives and muscle relaxants; and

c. a pharmaceutically acceptable acid or base being in sufficient quantity to adjust the pH of the composition to range from 2 to 9 and wherein the composition is liquid at about room temperature or below.

29. A method of treatment according to claim 28 wherein the polymer is one wherein w is 2.

30. A method of treatment according to claim 28 wherein the polymer is Tetronic.RTM. 1307.

31. A method of treatment according to claim 28 wherein the gel-sol transition temperature of the composition is room temperature or below and said composition is liquid at this temperature.

32. A method of treatment of claim 28 wherein said pharmaceutical composition is injected subcutaneously or intramuscularly.

33. A method of claim 32 wherein said pharmaceutical composition once injected may serve as a prolonged release site or depot.

34. A method of treatment according to claim 28 wherein the antibacterial substances are selected from the group consisting of beta-lactam antibiotics, tetracyclines, chloramphenicol, neomycin, gramicidin, bacitracin, sulfonamides, aminoglycoside antibiotics, tobramycin, nitrofurazone, nalidixic acid and analogs and the antimicrobial combination of fludalanine/pentizidone.

35. A method of treatment according to claim 28 wherein the antihistaminics and decongestants are selected from the group consisting of perilamine, chlorpheniramine, tetrahydrozoline and antazoline.

36. A method of treatment according to claim 28 wherein the anti-inflammatory drugs are selected from the group consisting of cortisone, hydrocortisone, betamethasone, dexamethasone, fluocortolone, prednisolone, triamcinalone, sulindac and its salts and corresponding sulfide.

37. A composition of claim 28 wherein the antiparasitic compound is ivermectin.

38. A method of treatment according to claim 28 wherein the antiviral effective compounds are selected from the group consisting of acyclovir and interferon.

39. A method of treatment according to claim 28 wherein the analgesic drug is selected from the group consisting of diflunisal, aspirin or acetaminophen.

40. A method of treatment according to claim 28 wherein the antiarthritics are selected from the group consisting of phenylbutazone, indomethacin, sulindac and its salts and corresponding sulfide, dexamethasone, ibuprofen, allopurinol, oxyphenbutazone or probenecid.

41. A method of treatment according to claim 28 wherein the antiasthma drugs are selected from the group consisting of theophylline, ephedrine, beclomethasone diproprionate and epinephrine.

42. A method of treatment according to claim 28 wherein the anticoagulants are selected from the group consisting of heparin, bishydroxycoumarin, and warfarin.

43. A method of treatment according to claim 28 wherein the anticonvulsants are selected from the group consisting of diphenylhydantoin and diazepam.

44. A method of treatment according to claim 28 wherein the antidepressants are selected from the group consisting of amitriptyline, chlordiazepoxide, perphenazine, protriptyline, imipramine and doxepin.

45. A method of treatment according to claim 28 wherein the antidiabetics are selected from the group consisting of insulin, somatostatin and its analogs, tolbutamide, tolazamide, acetohexamide and chlorpropamide.

46. A method of treatment according to claim 28 wherein the antineoplastics are selected from the group consisting of adriamycin, flurouracil, methotrexate and asparaginase.

47. A method of treatment according to claim 28 wherein the antipsychotics are selected from the group consisting of prochlorperazine lithium carbonate, lithium citrate, thioridazine, molindone, fluphenazine, trifluoperazine, perphenazine, amitriptyline and triflupromazine.

48. A method of treatment according to claim 28 wherein the antihypertensives are selected from the group consisting of spironolactone, methyldopa, hydralazine, clonidine, chlorothiazide, deserpidine, timolol, propranolol, metoprolol, prazosin hydrochloride and reserpine.

49. A method of treatment according to claim 28 wherein the muscle relaxants are selected from the group consisting of succinylcholine chloride, danbrolene, cyclobenzaprine, methocarbamol and diazepam.

50. A method of treatment according to claim 28 wherein the composition includes a buffering agent or salt of from 0% to 5% by weight of the composition.

51. A method of treatment according to claim 50 wherein the buffering agent or salt is selected from the group consisting of alkali or alkali earth carbonates, chlorides, sulfates, phosphates, bicarbonates, citrates, borates, acetates and succinates.

52. A method of treatment according to claim 28 wherein the composition includes from 0.001% to 5% by weight of the composition of a preservative.

53. A method of treatment according to claim 52 wherein the preservatives are selected from the group consisting of sodium bisulfite, sodium thiosulfate, ascorbate, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric borate, parabens, benzylalcohol and phenylethanol.

54. A method of treatment according to claim 28 wherein the acid or base is selected from the group consisting of hydrochloric acid or sodium hydroxide.

Details for Patent 4,474,752

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial Merck & Co., Inc. (Rahway, NJ) 2039-03-29 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Merck
Colorcon
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.